引用本文:邓 超,吾甫尔·依马尔.晚期甲状腺癌精准医疗的研究进展[J].中国临床新医学,2026,19(1):111-115.
【打印本页】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 39次   下载 53 本文二维码信息
码上扫一扫!
分享到: 微信 更多
晚期甲状腺癌精准医疗的研究进展
邓 超,吾甫尔·依马尔
新疆医科大学第一附属医院血管甲状腺外科,乌鲁木齐 830054
摘要:
[摘要] 晚期甲状腺癌因传统治疗效果有限,仍是临床难题。分子靶向治疗虽然可延长患者无进展生存期,但是耐药问题限制了其长期疗效;免疫治疗与靶向或放射性碘联合应用展现出协同潜力,然而整体疗效仍需进一步优化。该文对晚期甲状腺癌精准医疗的研究进展作一综述。
关键词:  晚期甲状腺癌  精准医疗  分子靶向治疗  免疫治疗
DOI:10.3969/j.issn.1674-3806.2026.01.19
分类号:R 736
基金项目:新疆维吾尔自治区自然科学基金资助项目(编号:2021D01C325)
Research progress in precision medicine for advanced thyroid cancer
DENG Chao, WUFUER Yimaer
Department of Blood Vessel and Thyroid Surgery, the First Teaching Hospital of Xinjiang Medical University, Urumqi 830054, China
Abstract:
[Abstract] Advanced thyroid cancer remains a clinical challenge due to the limited effectiveness of traditional treatments. Although molecular targeted therapy can prolong the progression-free survival of the patients, the problem of drug resistance limits its long-term effectiveness. The combination of immunotherapy with targeted therapy or radioiodine shows potential for synergy, but the overall efficacy still needs further optimization. In this paper, the research progress in precision medicine for advanced thyroid cancer is reviewed.
Key words:  Advanced thyroid cancer  Precision medicine  Molecular targeted therapy  Immunotherapy